A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.
Study Type
OBSERVATIONAL
Enrollment
60
Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi "G. d'Annunzio" di Chieti - Pescara
Chieti, CH, Italy
RECRUITINGProgression-free survival (PFS)
Progression-free survival (PFS) of patients with relapsed/refractory multiple myeloma undergoing allogeneic hematopoietic stem cell transplantation. PFS is defined as time from the date of allogeneic hematopoietic stem cell transplantation to the date of confirmed disease progression, or the date of death from any cause, whichever comes first.
Time frame: 10 years from the date of allogeneic hematopoietic stem cell transplantation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.